Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Cumberland Pharmaceuticals Inc (CPIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: CPIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.54% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.97M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta -0.29 | 52 Weeks Range 1.04 - 7.25 | Updated Date 07/12/2025 |
52 Weeks Range 1.04 - 7.25 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.98% | Operating Margin (TTM) 11.03% |
Management Effectiveness
Return on Assets (TTM) -2.7% | Return on Equity (TTM) -11.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40215879 | Price to Sales(TTM) 1.22 |
Enterprise Value 40215879 | Price to Sales(TTM) 1.22 | ||
Enterprise Value to Revenue 0.98 | Enterprise Value to EBITDA 12.36 | Shares Outstanding 14961100 | Shares Floating 7940923 |
Shares Outstanding 14961100 | Shares Floating 7940923 | ||
Percent Insiders 41.54 | Percent Institutions 28.76 |
Upturn AI SWOT
Cumberland Pharmaceuticals Inc
Company Overview
History and Background
Cumberland Pharmaceuticals Inc. was founded in 1999 and is headquartered in Nashville, Tennessee. The company focuses on the acquisition, development, and commercialization of branded prescription products. Initially concentrating on hospital products, Cumberland has expanded into broader therapeutic areas through strategic acquisitions and internal development.
Core Business Areas
- Hospital Products: This segment focuses on providing branded prescription products for the acute care hospital setting. Key products include Caldolor (ibuprofen injection) and Ofirmev (acetaminophen injection).
- Gastrointestinal Products: This segment includes prescription products that are designed for the relief of various symptoms associated with gastrointestinal issues.
- Dermatology: This segment includes prescription products that are designed for dermatological needs, particularly treatment of skin-related diseases
Leadership and Structure
Cumberland Pharmaceuticals Inc. is led by a team of executives with experience in the pharmaceutical industry. The structure is organized around functional areas, including research and development, sales and marketing, and finance and operations. The CEO is John Hammann.
Top Products and Market Share
Key Offerings
- Ofirmev (acetaminophen injection): Ofirmev is an intravenous formulation of acetaminophen used for pain management and fever reduction in hospitals. Competitors include generic acetaminophen injections, IV ibuprofen and opioid analgesics. Market share data is not publicly available, but Ofirmev is a leading brand in its niche.
- Caldolor (ibuprofen injection): Caldolor is an intravenous formulation of ibuprofen used for pain management and fever reduction in hospitals. Competitors include generic ibuprofen injections, IV acetaminophen, and opioid analgesics. Market share data is not publicly available, but Caldolor is a significant player in the market.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Increasing generic competition and pricing pressures are significant challenges. Technological advancements and personalized medicine are driving innovation.
Positioning
Cumberland Pharmaceuticals Inc. occupies a niche position, focusing on hospital-based and specialty pharmaceuticals. Its competitive advantages include established brands and a focused portfolio of products.
Total Addressable Market (TAM)
The TAM for acute pain and fever management is estimated to be several billion dollars annually in the US. Cumberland is positioned to capture a portion of this TAM through its hospital-based products.
Upturn SWOT Analysis
Strengths
- Established brands in niche markets
- Focused product portfolio
- Experienced management team
- Strong relationships with hospitals
Weaknesses
- Small market capitalization
- Reliance on a limited number of products
- Limited R&D pipeline
- Vulnerability to generic competition
Opportunities
- Strategic acquisitions
- New product development
- Geographic expansion
- Partnerships and collaborations
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- Pacira BioSciences (PCRX)
- Assertio Holdings (ASRT)
- Mallinckrodt (MNK)
Competitive Landscape
Cumberland faces competition from both generic and branded pharmaceutical companies. Its advantages include established brands in niche markets, while its disadvantages include limited scale and R&D resources.
Growth Trajectory and Initiatives
Historical Growth: Cumberland's growth has been driven by product sales and strategic acquisitions. Growth rates have varied depending on product performance and market conditions.
Future Projections: Future growth is dependent on new product launches, market penetration, and cost management. Analyst estimates vary widely depending on the company's performance and market conditions.
Recent Initiatives: Recent initiatives include new product launches and collaborations to expand their portfolio.
Summary
Cumberland Pharmaceuticals is a niche player with established hospital products and growth potential. Its small size and reliance on a limited number of products pose challenges. The company must continue to diversify its product portfolio through acquisitions and internal development. Success will depend on execution, cost control, and navigating the evolving pharmaceutical landscape. The company has to beware of competition from generic brands.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change. Accuracy of financial data is dependent on reliable sources. Market share data can be estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cumberland Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2009-08-11 | Founder, Chairman, President & CEO Mr. A. J. Kazimi MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 91 | Website https://www.cumberlandpharma.com |
Full time employees 91 | Website https://www.cumberlandpharma.com | ||
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.